<DOC>
	<DOCNO>NCT02489760</DOCNO>
	<brief_summary>To determine safety efficacy switch effect adalimumab etanercept-treated AS patient .</brief_summary>
	<brief_title>Etanercept Versus Adalimumab Treatment Patients With Ankylosing Spondylitis . A Switch Study</brief_title>
	<detailed_description>This single-centre , open-labeled randomize control study evaluate safety efficacy adalimumab etanercept-treated Ankylosing Spondylitis ( AS ) patient . Thirty patient enrol randomize equally two arm . Dosage Administration：For standard dose ( etanercept 50 mg weekly ) treat patient , treatment arm receive adalimumab 40 mg subcutaneously biweekly 8 week . The control arm continue etanercept 25 mg subcutaneously twice week 8 week . At week 8 , control arm switch adalimumab 40 mg subcutaneously biweekly another 8 weeks.For half dose ( etanercept 25 mg weekly ) treat patient , treatment arm receive adalimumab 40 mg subcutaneously monthly 8 week . The control arm continue etanercept 25 mg subcutaneously weekly 8 week . At week 8 , control arm switch adalimumab 40 mg subcutaneously monthly another 8 week .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Diagnosis AS , define 1984 Modified New York Criteria AS . Stable background therapy nonsteroid antiinflammatory 2 week . Stable glucocorticoid 4 week . Stable diseasemodifying antirheumatic drug , eg . sulphasalazine , methotrexate 8 week . Stable antiTNF biologics 4 week . Written informed consent . Serum creatinine ≥3.0 mg/dl . GPT≥5 time laboratory 's upper limit normal . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Etanercept</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>Switch Study</keyword>
</DOC>